Kazia Therapeutics released its April 2026 corporate overview, highlighting paxalisib clinical progress, pipeline advancements for NDL2 and MSETC, US$46 million cash runway into 2029, and upcoming 2026 milestones.
Key takeaways
Cash and equivalents approximately US$46 million, runway into 2029 excluding additional trials, no outstanding debt.
Paxalisib: Phase 1b TNBC study ongoing with complete metabolic response in stage IV expanded access patient and two partial responses reported January 2026.
NDL2 PD-L1 protein degrader and MSETC SETDB1 inhibitor advancing to IND-initiating studies commencing 2026.
Q4 2025: Pricing of $50 million private placement; Q1 2026: NDL2 preclinical data update and CSO appointment.
FDA designations for paxalisib include Fast Track, Orphan Drug, and Rare Pediatric Disease.